- Home
- VNDA vs YMAB Comparison
VNDA vs YMAB Comparison
Compare VNDA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- YMAB
- Stock Information
- Founded
- VNDA 2002
- YMAB 2015
- Country
- VNDA United States
- YMAB United States
- Employees
- VNDA N/A
- YMAB N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- YMAB Health Care
- Exchange
- VNDA Nasdaq
- YMAB Nasdaq
- Market Cap
- VNDA 282.8M
- YMAB 270.5M
- IPO Year
- VNDA 2006
- YMAB 2018
- Fundamental
- Price
- VNDA $4.98
- YMAB $4.67
- Analyst Decision
- VNDA Strong Buy
- YMAB Buy
- Analyst Count
- VNDA 2
- YMAB 11
- Target Price
- VNDA $16.50
- YMAB $19.64
- AVG Volume (30 Days)
- VNDA 778.6K
- YMAB 408.2K
- Earning Date
- VNDA 05-07-2025
- YMAB 03-04-2025
- Dividend Yield
- VNDA N/A
- YMAB N/A
- EPS Growth
- VNDA N/A
- YMAB N/A
- EPS
- VNDA N/A
- YMAB N/A
- Revenue
- VNDA $198,772,000.00
- YMAB $87,685,000.00
- Revenue This Year
- VNDA $14.36
- YMAB $20.07
- Revenue Next Year
- VNDA $44.53
- YMAB $8.76
- P/E Ratio
- VNDA N/A
- YMAB N/A
- Revenue Growth
- VNDA 3.18
- YMAB 3.38
- 52 Week Low
- VNDA $3.71
- YMAB $4.25
- 52 Week High
- VNDA $6.75
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- VNDA 58.23
- YMAB 31.48
- Support Level
- VNDA $4.84
- YMAB $4.62
- Resistance Level
- VNDA $5.10
- YMAB $5.03
- Average True Range (ATR)
- VNDA 0.24
- YMAB 0.37
- MACD
- VNDA 0.02
- YMAB -0.01
- Stochastic Oscillator
- VNDA 76.40
- YMAB 27.45
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.